Participated · Series D · Sep 2025

Founded in 2020, Thyme Care builds an integrated oncology infrastructure that aligns payers, providers, employers, and patients around value-based care. Its technology stack combines AI-driven orchestration, advanced data analytics, and a virtual/hybrid care team of doctors, nurses, social workers, and care partners to guide patients through every stage of the cancer journey. The company now partners with more than 1,000 oncologists and reaches 8 million covered lives, managing over $5 billion in oncology spend. Outcomes include 90% of members feeling more supported, 72% proactively submitting ePRO updates, 40% fewer ER visits, and 19% fewer hospital admissions among engaged members. One partner practice saved nearly 2,000 staff hours in a year, underscoring efficiency gains. Thyme Care achieved profitability ahead of its Series D raise, demonstrating a sustainable business model. Looking forward, the company plans to deepen AI integration to automate documentation, surface real-time insights, and eliminate additional bottlenecks in cancer care. By scaling these capabilities, Thyme Care aims to serve as the backbone for more connected, accountable, and compassionate oncology care nationwide.

Participated · Equity · Sep 2024

Pieces Technologies builds cloud-based clinical generative AI and ensemble-AI solutions to support inpatient care teams and streamline clinician workflows. The company applies applied clinical generative AI, adversarial and collaborative AI, predictive modeling, and physician-supervised machine learning to improve patient, financial, and operational outcomes. Led by CEO Ruben Amarasingham, Pieces specializes in generating inpatient clinical summaries and other clinician-facing tools for health systems. As of September 10, 2024, the company has generated more than 5.4 million inpatient clinical summaries across multiple health system clients. Pieces intends to use new funding to deploy its AI-driven solutions nationwide. The company is headquartered in Dallas, TX. Pieces Technologies develops healthcare artificial intelligence and technology to link health systems with community organizations for addressing clinical and social determinants of health. Its core products are the Pieces Decision Sciences (DS) clinical analytics engine and the Pieces Iris® social determinants of health (SDoH) platform. Since 2016, Pieces has been building integrated communities between health systems and community service providers. Its clients include hospitals, health systems, health plans, community health clinics and community service providers such as food banks, job assistance and educational services. In January 2020 the company closed a $25.7 million Series B to accelerate national distribution of its Decision Sciences and Iris platforms. Pieces Technologies develops the Pieces™ software platform, a predictive, cloud-based health information technology that offers integrated monitoring, prediction, workflow optimization, and organizational learning for hospitals, health systems, and community-based organizations. The platform interprets patient data in real time using predictive models and clinical research to create warning tools intended to identify and prevent adverse events such as avoidable mortality and re-hospitalization. Pieces Tech also provides cloud-based software for community organizations to manage client needs and connects to hospital information systems to offer a holistic view of patients. The Pieces™ platform was incubated at the Parkland Center for Clinical Innovation, and Parkland has reported benefits from its use. Children’s Health is working with Pieces to advance and co-develop technology for earlier interventions in pediatric chronic conditions. Founder and CEO Ruben Amarasingham, M.D., leads the company as it readies for broader marketplace expansion following its Series A financing.

Led · Series B · Jul 2024

Loyal’s AI-powered consumer engagement platform helps health systems consolidate disparate technology stacks, streamline patient navigation, and drive care utilization across the patient journey. The platform is used by a customer base of 38 health systems and the company reports a track record of continued revenue growth. Loyal says its solution makes it easier for patients to connect with care and drives loyalty to health providers. The recent financing is intended to fund expansion of the customer base, further product development, bolster customer success, and accelerate growth. As part of its growth plans the company announced executive and board changes to support scaling efforts. Loyal is headquartered in Atlanta. Loyal offers a proprietary, end-to-end digital and AI-powered consumer experience platform designed to streamline the patient journey — from provider selection and scheduling to closing the feedback loop. The company focuses on improving care utilization and patient engagement among hospitals and health systems. Loyal's platform is used by more than 30 hospitals and health systems, including Northwestern Medicine and UCLA Health, and the company has reported significant commercial growth. The announced funds will be used to enhance and expand the existing platform and to secure talent and resources to realize a personalized patient experience across all aspects of care. Loyal positions itself as a healthcare consumer experience company dedicated to making access to care easier and increasing patient loyalty. The company highlights its role in helping health systems remain engaged with patients during a tumultuous period for hospitals.

Led · Series D · Jul 2022

Accelus develops expandable spinal implant technologies and markets a portfolio of implants and instruments for minimally invasive spine surgery. Its products include the FlareHawk Interbody Fusion System with Adaptive Geometry technology, the LineSider Spinal System with modular-cortical screws, and the Toro-L Interbody Fusion System. The company designs implants and instruments for a range of techniques across hospital and ambulatory surgery center settings. Accelus reports more than 32,000 cages implanted in 25 countries, which the company cites as a foundation for growth. The new equity financing will support continued commercial expansion, deepen U.S. market presence, and fund pipeline innovation, including expansion of the FlareHawk and Toro portfolios. In conjunction with the financing, Accelus appointed industry veteran Bernie Haffey as chairman of the board to help oversee the next phase of growth. Accelus develops expandable interbody fusion implants, including its flagship FlareHawk and Toro systems, and emphasizes Adaptive Geometry™ technology for better endplate conformity. The company positions itself as a worldwide leader in expandable spinal implant solutions and targets multiple surgical approaches (TLIF, PLIF, endoscopic-assisted, percutaneous, and lateral). Accelus plans to expand its sales force into underpenetrated markets and to accelerate clinical research and product development around its core implants. The firm is pursuing additional clinical studies and data collection to reinforce the clinical efficacy of FlareHawk, which prior reports have linked to favorable fusion and patient outcomes. The company says the funding will strengthen its balance sheet and support R&D and broader market reach. Accelus is headquartered in Palm Beach Gardens, Florida. Accelus develops and commercializes an ecosystem of spinal implants, instruments, biologics, and enabling technologies centered on minimally invasive surgery. Its portfolio includes the FlareHawk Interbody Fusion System with proprietary multidirectional expansion technology and the Robotic-Enabled Minimally Invasive (Remi) targeting and navigation platform. The company focuses on improving access to MIS techniques in both hospitals and ambulatory surgery centers. Accelus plans to use its recent funding to drive further adoption and commercialization of its product portfolio across the U.S. market. Led by CEO and co-founder Chris Walsh, the company aims to address clinical challenges associated with spine surgery through less disruptive implants and robotic guidance. The company is based in Palm Beach Gardens, Florida.

Led · Series B · Apr 2022

Iris Telehealth provides telepsychiatry services to health systems and community health centers across the U.S., supplying clinicians, staff support, and operational know-how to build sustainable telepsychiatry departments. The company identifies best-fit providers for each partner and emphasizes long-term commitment to meeting partner needs. Founded in 2013 and led by CEO Andy Flanagan, Iris now serves almost 200 hospitals and community health centers. The business plans to use recent funding to grow its clinical operations team and augment both clinical and corporate staff. It also intends to scale its go-to-market strategy and expand product and technology capabilities. Iris raised a $40M Series B to fund these growth and product initiatives.